Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
421 to 440 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Study design and rationale for the NeoTRACE trial: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer. | Future Oncol | 2025 | 41268635 | PubTator, text mining | PubMed |
| Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity. | J Med Chem | 2025 | 41267393 | PubTator, text mining | PubMed |
| Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development. | NPJ Precis Oncol | 2025 | 41261175 | PubTator, text mining | PubMed |
| Inhibiting TROP2 in advanced non-small-cell lung cancer with sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan: similarities and differences. | Cancer Chemother Pharmacol | 2025 | 41258931 | PubTator, text mining | PubMed |
| Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report. | Cureus | 2025 | 41257122 | PubTator, text mining | PubMed |
| Abstracts of the Annual Conference of the German Society for Biological Radiation Research (DeGBS) : Munich, Germany. 29 September-1 October 2025. | Radiat Oncol | 2025 | 41254773 | PubTator, text mining | PubMed |
| AXINEO: AXIllary response to NEOadjuvant chemotherapy for breast cancer: can we predict response based on a biomarker panel? | Arch Gynecol Obstet | 2025 | 41251718 | PubTator, text mining | PubMed |
| Isothermal nucleic acid amplification-based magnetic aptasensor for sensitive detection and in situ imaging of Trop-2 in triple-negative breast cancer. | Anal Chim Acta | 2025 | 41241473 | PubTator, text mining | PubMed |
| A Covalent Click Chemistry Chip for Highly Efficient Capture and Brightfield Identification of Circulating Tumor Cells. | Anal Chem | 2025 | 41231096 | PubTator, text mining | PubMed |
| Efficacy and safety of datopotamab deruxtecan in advanced/metastatic non-small cell lung cancer patients: a systematic review and single-arm meta-analysis. | J Thorac Dis | 2025 | 41229829 | PubTator, text mining | PubMed |
| Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease. | Cancers (Basel) | 2025 | 41228204 | PubTator, text mining | PubMed |
| [Personalized systemic therapy of penile cancer: molecular targets and new therapeutic horizons]. | Urologie | 2025 | 41222675 | PubTator, text mining | PubMed |
| [Advances in antibody-conjugating drugs in prostate cancer: applications and challenges]. | Zhonghua Wai Ke Za Zhi | 2025 | 41216731 | PubTator, text mining | PubMed |
| De novo discovery and preclinical evaluation of a novel peptide radiotracer for PET imaging of TROP-2 in non-small cell lung cancer. | Bioorg Chem | 2025 | 41205472 | PubTator, text mining | PubMed |
| Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer. | NPJ Breast Cancer | 2025 | 41203648 | PubTator, text mining | PubMed |
| Noninvasive Evaluation of Trop2 Expression Using 64Cu-NOTA-Trodelvy-F(ab')2 in Gastric and Pancreatic Cancer. | Mol Pharm | 2025 | 41201395 | PubTator, text mining | PubMed |
| Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer. | Ann Med Surg (Lond) | 2025 | 41180655 | PubTator, text mining | PubMed |
| FDA approves second-line TROP2-directed antibody-drug conjugate Dato-DXd for EGFR-mutated NSCLC. | Cancer | 2025 | 41178651 | PubTator, text mining | PubMed |
| Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling. | Cell Rep Med | 2025 | 41172996 | PubTator, text mining | PubMed |
| Deep Mutational Scanning in Immunology: Techniques and Applications. | Pathogens | 2025 | 41156637 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=22